Related Experiment Video

Updated: Aug 29, 2025

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain
04:50

Preliminary Study on Acupuncture Combined with Grain-sized Moxibustion for Treating Rheumatoid Arthritis with Finger Joint Pain

Published on: May 16, 2025

316

Emerging therapies for juvenile arthritis: agents in early clinical trials

Silvia Rosina1, Gabriella Giancane1,2, Nicolino Ruperto1,3

  • 1Clinica Pediatrica e Reumatologia, IRCCS Istituto Giannina Gaslini, Genova, Italy.

Expert Opinion on Investigational Drugs
|September 6, 2022
PubMed

Insights

New drugs are revolutionizing juvenile idiopathic arthritis (JIA) treatment, with ongoing clinical trials focusing on specific JIA categories and early-phase investigational agents for improved childhood arthritis management.

Area of Science:

  • Pediatric rheumatology
  • Inflammatory diseases
  • Pharmacology

Background:

  • Juvenile idiopathic arthritis (JIA) is the most prevalent chronic inflammatory rheumatic disease in children.
  • Recent advancements in drug development and clinical trial methodologies have transformed JIA management.
  • International collaborations and legislative support facilitate research in JIA.

Purpose of the Study:

  • To review the latest advancements in JIA treatment.
  • To focus on novel investigational drugs currently in or recently completed early-phase clinical development for JIA.
  • To highlight unmet needs and future research directions in pediatric arthritis.

Main Methods:

  • Review of current literature on JIA treatment.
  • Focus on early-phase clinical trials for new JIA therapies.
  • Analysis of recent drug development in pediatric rheumatology.

Main Results:

  • Significant progress in JIA management due to new powerful drugs.
  • Ongoing clinical trials are investigating novel agents for specific JIA categories.
  • Early-phase development includes promising investigational drugs for JIA.

Conclusions:

  • Despite progress, unmet needs in JIA treatment persist.
  • Further research into disease pathogenesis may identify new targets for refractory JIA.
  • Development of predictive biomarkers for treatment efficacy and safety is crucial for personalized JIA care.
Abstract

Keywords:
BiologicsJAK inhibitorclinical trialsinvestigational drugsjuvenile idiopathic arthritissmall molecules

More Related Videos

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice07:37

An Adoptive Transfer Model of Rheumatoid Arthritis in Mice

Published on: June 6, 2025

327
Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats04:38

Author Spotlight: Assessing Intrathecal Gene Therapy Efficacy in Juvenile Rats

Published on: March 29, 2024

1.3K

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
257
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
216
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
3.3K
Inflammatory Bowel Disease IV: Pharmacological Management01:29

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
174
Clinical Trials01:16

Clinical Trials

Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
7.0K
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
194